Choosing Between the Decentralised and Mutual Recognition Procedures: RMS Strategy and the Road to a Greek Licence

For most generic, hybrid and well-established medicines, the route to a Greek marketing authorisation runs through the decentralised procedure (DCP) or the mutual recognition procedure (MRP) rather than the centralised system. Both are coordinated through the CMDh and both depend on one decision made early: which Member State acts as Reference Member State (RMS), and what the dossier looks like when it lands there.

DCP or MRP: the core difference

Under Directive 2001/83/EC, the two procedures answer different starting points:

  • DCP is used when the product has no marketing authorisation anywhere in the EU. The RMS prepares the assessment, and the Concerned Member States (CMS), which can include Greece, review it in parallel. The procedure runs for roughly 210 days of active time, excluding clock stops, followed by a national phase of about 30 days.
  • MRP is used when a national authorisation already exists in one Member State, which then acts as RMS. The CMS review that existing assessment on a 90-day timetable, and national licences follow about 30 days after closure.

The practical consequence is that DCP lets you launch in several markets at the same time, while MRP lets you start in one market and extend later, with the existing assessment report as the anchor.

Choosing the RMS

The RMS is more than an administrative choice. It sets the pace of the procedure, shapes the questions you receive and defines the reference text everyone else works from. Points worth weighing include the authority’s scheduling capacity, its experience with your product type, language and communication practicalities, and how its national requirements differ from the harmonised dossier. A poorly matched RMS can add months through slow queries or a weak assessment report that other Member States then challenge.

Where procedures go wrong

Most delays do not come from the scientific core of the dossier. Typical causes include:

  • Quality or bioequivalence questions raised late by a CMS rather than resolved with the RMS.
  • Inconsistent product information and national annexes across Member States.
  • Late or incomplete translations after procedure closure.
  • Unresolved objections that escalate to the CMDh when consensus is not reached.

If disagreement persists and a CMS raises a potential serious risk to public health, the matter can move to a referral under Article 29(4), where the CHMP issues an opinion that leads to a binding European Commission decision. It is a rare outcome, but one that is worth planning around when the dossier contains known weak points. The MRP best practice guide also makes clear that issues already discussed and agreed should not be reopened without new information, which is a strong reason to keep the first assessment robust.

Preparing for Greece as a CMS

When Greece is a Concerned Member State, the EOF reviews the RMS assessment and the national requirements still apply: Greek labelling and leaflet text, local pricing and reimbursement steps, and the practical readiness of the supply chain. Starting national preparation in parallel with the procedure, rather than after closure, shortens the time between licence and launch.

How PQRA helps

PQRA supports DCP and MRP strategy from the outset: choosing the route and RMS, assembling and reviewing the dossier, managing responses to CMS queries, coordinating translations and national annexes, and linking the Greek licence to pricing and market-access planning.

Planning a multi-country filing that includes Greece? Contact PQRA to discuss your procedure.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *